Search results
Results from the WOW.Com Content Network
Treatment of testicular cancer is one of the success stories of modern medicine, with sustained response to treatment in more than 90% of cases, regardless of stage. [53] In 2011 overall cure rates of more than 95% were reported, and 80% for metastatic disease—the best response by any solid tumor, with improved survival being attributed ...
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
PT-DLBCL is by far the most common form of testicular cancer in men >60 years of age. [2] It usually develops in this age group (median age ~65 years old, range 10–96 years) and presents as a painless testicular mass or swelling in one testis or, in ~6% of cases, both testes: [1] PT-DLBCL is the most common testicular cancer to present with disease in both testicles. [8]
It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered in early stages. [3] Testicular seminoma originates in the germinal epithelium of the seminiferous tubules. [4] About half of germ cell tumors of the testicles are seminomas. [5] Treatment usually requires removal of one ...
In the testis pure embryonal carcinoma is also uncommon, and accounts for approximately ten percent of testicular germ cell tumours. However, it is present as a component of almost ninety percent of mixed nonseminomatous germ cell tumours. The average age at diagnosis is 31 years, and typically presents as a testicular lump which may be painful.
As is the case for all reproductive cancers, a degree of caution is taken when deciding to use adjuvant therapy to treat early stage testicular cancer. Though the 5-year survival rates for stage I testicular cancers is approximately 99%, there still exists controversy over whether to overtreat stage I patients to prevent relapse or to wait ...
With the advent of multiagent chemotherapy after surgical resection, long-term remission and increased survival rates have been achieved. Pashankar et al. (2016) , reported that the estimated 5-year overall survival rate for grade 3 Stage I and II disease was 91% compared with 88% for grade 3, Stage III and IV disease.
For example, adolescents and young adults with acute lymphoblastic leukemia (ALL) may have better outcomes if they are treated with pediatric treatment protocols rather than adult treatment protocols. The 5-year survival rates for 15- to 19-year-olds with ALL has risen to 74% as of 2007–2013, from survival rates of around 50% in the early 1990s.